The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NEXT: A phase 2 study of nivolumab adjuvant to chemoradiation in patients (pts) with localized urothelial carcinoma.
 
Gliceida Galarza Fortuna
No Relationships to Disclose
 
G. Daniel Grass
Employment - Moffitt Cancer Center and Research Institute
Stock and Other Ownership Interests - Editas Medicine; G1 Therapeutics; GlycoMimetics; Halozyme; Intellia Therapeutics; Lantheus Medical Imaging
Consulting or Advisory Role - MyCareGorithm
Patents, Royalties, Other Intellectual Property - MODELING VARIABILITY IN RADIOSENSITIVITY AND TUMOR IMMUNE CONTEXTURE TO PERSONALIZE RADIOTHERAPY
 
Benjamin L. Maughan
Consulting or Advisory Role - Astellas Medivation; AVEO; Bavarian Nordic; Bayer; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Janssen Oncology; Merck; Peloton Therapeutics; Pfizer; Tempus
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Rohit K. Jain
Honoraria - Curio Science; DAVA Oncology; FLASCO; MJH Life Sciences
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; EMD Serono; Gilead Sciences; Sanofi
Speakers' Bureau - Seattle Genetics/Astellas
Research Funding - Bristol Myers Squibb; Gilead Sciences; NCI
Travel, Accommodations, Expenses - DAVA Oncology; FLASCO; Sanofi
 
Christopher B. Dechet
No Relationships to Disclose
 
Julia Beck
Employment - Chronix Biomedical; Oncocyte
Patents, Royalties, Other Intellectual Property - Inventor of several patents filed by Chronix Biomedical
 
Ekkehard Schuetz
Employment - Ocncocyte
Leadership - OncoCyte
Stock and Other Ownership Interests - Oncocyte
Patents, Royalties, Other Intellectual Property - Several issued patent in the field of cell-free DNA diagnostics
Travel, Accommodations, Expenses - OncoCyte
 
Alejandro Sanchez
No Relationships to Disclose
 
Brock ONeil
No Relationships to Disclose
 
Michael Adam Poch
No Relationships to Disclose
 
Roger Li
Stock and Other Ownership Interests - Beam Therapeutics; crispr therapeutics; Editas Medicine; Guardant Health; Intellia Therapeutics; Lilly
Consulting or Advisory Role - Arquer Diagnostics; Bristol-Myers Squibb; CG Oncology; FerGene; Ferring; Lucence Diagnostics; Merck; Urogen pharma
Research Funding - CG Oncology; Predicine
Expert Testimony - CG Oncology
Travel, Accommodations, Expenses - CG Oncology
Other Relationship - Predicine
 
Shane Lloyd
Honoraria - Sirtex Medical
Consulting or Advisory Role - Cancer Study Group
Expert Testimony - Kipp and Christian
 
Jonathan David Tward
Honoraria - Bayer
Consulting or Advisory Role - Bayer; Bayer; Blue Earth Diagnostics; Boston Scientific; Boston Scientific; Janssen Scientific Affairs; Lantheus Medical Imaging; Merck; Myovant Sciences; Myriad Genetics; Myriad Genetics; Myriad Genetics
Research Funding - Bayer (Inst); Myriad Genetics (Inst)
Expert Testimony - Expert Consulting Services
Travel, Accommodations, Expenses - Bayer; Myriad Genetics
 
Tenzin Kunsang Phunrab
No Relationships to Disclose
 
Josiah Hawks
No Relationships to Disclose
 
Umang Swami
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Exelixis; Imvax; Pfizer; Sanofi; Seagen
Research Funding - Exelixis (Inst); Janssen (Inst); Seattle Genetics/Astellas (Inst)
 
Kenneth M. Boucher
No Relationships to Disclose
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Sumati Gupta
Stock and Other Ownership Interests - Salarius Pharmaceuticals (I)
Research Funding - Acrotech Biopharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/Lilly (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); Immunocore (Inst); Incyte (Inst); LSK BioPharma (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); QED Therapeutics (Inst); Rexahn Pharmaceuticals (Inst); Seagen (Inst); Viralytics (Inst)
Travel, Accommodations, Expenses - QED Therapeutics
(OPTIONAL) Uncompensated Relationships - Astellas Pharma